<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-124
TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P.
-------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3166762
- ------------------------------- ---------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2000 Alameda de las Pulgas, Suite 250
San Mateo, California 94403
- --------------------------------------- --------
(Address of principal executive offices) (Zip Code)
(650) 345-2200
--------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
No active market for the units of limited partnership interests
("Units") exists, and therefore the market value of such Units cannot be
determined.
<PAGE>
I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
- --------------
<TABLE>
<CAPTION>
(unaudited)
June 30, December 31,
1999 1998
------------ ------------
<S> <C> <C>
ASSETS
Equity investments (cost basis of
$4,026,183 and $4,208,359 in 1999
and 1998, respectively) $5,864,535 5,671,650
Cash and cash equivalents 3,376 387
Other assets 6,593 920
--------- ---------
Total assets $5,874,504 5,672,957
========= =========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 40,944 38,899
Due to related parties 414,898 84,157
Short-term borrowings 182,247 202,436
--------- ---------
Total liabilities 638,089 325,492
Commitments, contingencies and
subsequent event (Notes 3 and 6)
Partners' capital:
Limited Partners (79,716 Units
outstanding) 3,428,731 3,909,982
General Partners (30,668) (25,808)
Net unrealized fair value increase
from cost of equity investments 1,838,352 1,463,291
--------- ---------
Total partners' capital 5,236,415 5,347,465
--------- ---------
Total liabilities and
partners' capital $5,874,504 5,672,957
========= =========
</TABLE>
See accompanying notes to financial statements.
<PAGE>
STATEMENTS OF OPERATIONS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Three For the Six
Months Ended Months Ended
June 30, June 30,
----------------------- -----------------------
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Income:
Short-term investment interest $ -- 472 -- 696
Dividend income 3,946 3,498 7,978 7,947
-------- ------- ------- -------
Total income 3,946 3,970 7,978 8,643
Costs and expenses:
Management fees 39,649 39,649 79,298 79,298
Individual General Partners'
compensation 8,914 11,069 18,549 15,368
Amortization of organizational costs -- 2,000 -- 4,000
Operating expenses:
Administrative and investor services 74,722 54,266 126,797 105,560
Investment operations 14,370 2,581 27,013 28,463
Professional fees 23,004 9,744 29,568 15,222
Computer services 8,676 12,291 20,877 27,266
Interest expense 5,188 -- 9,811 --
Expenses absorbed by General Partners -- (62,535) -- (62,535)
-------- ------- ------- -------
Total operating expenses 125,960 16,347 214,066 113,976
-------- -------- ------- -------
Total costs and expenses 174,523 69,065 311,913 212,642
-------- -------- ------- -------
Net operating loss (170,577) (65,095) (303,935) (203,999)
Net realized loss from sales
of equity investments -- -- -- (400)
Realized losses from investment
write-downs (182,176) -- (182,176) --
-------- ------- ------- -------
Net realized loss (352,753) (65,095) (486,111) (204,399)
Change in net unrealized fair
value of equity investments 135,167 102,757 375,061 (151,352)
-------- ------- ------- -------
Net (loss) income $(217,586) 37,662 (111,050) (355,751)
======== ======= ======= =======
Net realized loss per Unit $ (4.38) (0.81) (6.04) (2.54)
======== ======= ======= =======
</TABLE>
See accompanying notes to financial statements.
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Six Months Ended June 30,
------------------------------------
1999 1998
------ ------
<S> <C> <C>
Cash flows from operating activities:
Interest received $ -- 696
Dividend income received 7,978 7,947
Cash paid to vendors (97,703) (37,351)
Cash advanced by (paid to) related
parties, net 112,903 (129,582)
------- -------
Net cash provided (used) by operating
activities 23,178 (158,290)
------- -------
Cash flows from investing activities:
Proceeds from the sales of equity
investments -- 2,730
------- -------
Net cash provided by investing activities -- 2,730
------- -------
Cash flows from financing activities:
Repayment of short-term borrowings, net (20,189) --
------- -------
Net cash used by financing activities (20,189) --
Net increase (decrease) in cash and
cash equivalents 2,989 (155,560)
Cash and cash equivalents at beginning
of year 387 157,137
------- -------
Cash and cash equivalents at June 30 $ 3,376 1,577
======= =======
Reconciliation of net loss to net cash
provided (used) by operating activities:
Net loss $(111,050) (355,751)
Adjustments to reconcile net loss to net
cash provided (used) by operating
activities:
Amortization of organizational costs -- 4,000
Change in net unrealized fair value
of equity investments (375,061) 151,352
Net realized loss from sales of equity
investments -- 400
Realized losses from investment
write-downs 182,176 --
Changes in:
Accounts payable and accrued expenses 2,045 (9,993)
Due to related parties 330,741 52,254
Other changes, net (5,673) (552)
------- -------
Net cash provided (used) by operating
activities $ 23,178 (158,290)
======= =======
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NOTES TO FINANCIAL STATEMENTS (unaudited)
- ----------------------------------------
1. General
-------
In the opinion of the Managing General Partners, the accompanying interim
financial statements reflect all adjustments necessary for a fair
presentation of the financial position, results of operations, and cash
flows for the interim periods presented. These statements should be read
in conjunction with the Annual Report on Form 10-K for the year ended
December 31, 1998. Allocation of income and loss to Limited and General
Partners is based on cumulative income and loss. Adjustments, if any, are
reflected in the current quarter balances.
2. Financing of Partnership Operations
-----------------------------------
The Managing General Partners expect cash received from the future
liquidation of Partnership investments and short-term borrowings will
provide the necessary liquidity to fund Partnership operations. The
Partnership may be dependent upon the financial support of the Managing
General Partners to fund operations if future proceeds are not received
timely. The Managing General Partners have committed to support the
Partnership's working capital requirements through short-term advances as
necessary.
3. Related Party Transactions
--------------------------
Related party costs are included in costs and expenses shown on the
Statements of Operations. Related party costs for the six months ended
June 30, 1999 and 1998, were as follows:
<TABLE>
<CAPTION>
1999 1998
------ ------
<S> <C> <C>
Management fees $ 79,298 79,298
Individual General Partners' compensation 18,549 15,368
Reimbursable operating expenses 119,991 149,705
Expenses absorbed by General Partners -- (62,535)
</TABLE>
Certain reimbursable expenses have been accrued based upon interim
estimates prepared by the Managing General Partners and are adjusted to
actual costs periodically. Amounts due to related parties for such
expenses were $348,816 and $60,724 at June 30, 1999 and at December 31,
1998, respectively.
Pursuant to the Partnership Agreement, the Partnership shall reimburse the
Managing General Partners for operational costs incurred by the Managing
General Partners in conjunction with the business of the Partnership. The
Partnership may not reimburse the Managing General Partners for operational
costs that aggregate more than 3% of total Limited Partner capital
contributions of the Partnership in each year through the first five years
of operations after the termination of unit sales and 1.5% in any year
thereafter. For purposes of this limitation, the Partnership's operating
year begins May 3rd. For the six months ended June 30, 1998, the Managing
General Partners absorbed $62,535 in operating expenses. No such expenses
were absorbed for the six months ended June 30, 1999.
Management fees payable were $66,082 and $23,433 at June 30, 1999 and
December 31, 1998, respectively.
<PAGE>
4. Equity Investments
------------------
<TABLE>
A complete listing of the Partnership's equity investments at December 31, 1998, is in the
1998 Annual Report on Form 10-K. Activity from January 1 through June 30, 1999, consisted of:
<CAPTION>
January 1 through
June 30, 1999
------------------------
Principal
Investment Amount or Cost Fair
Industry/Company Position Date Shares Basis Value
- ---------------- -------- ---------- ---------- --------- ---------
<S> <C> <C> <C> <C> <C>
Balance at January 1, 1999 $4,208,359 5,671,650
--------- ---------
Significant changes:
Environmental
- -------------
Naiad Technologies, Series A, B
Inc. and C
Preferred 12/95-
shares 11/97 161,832 0 (215,753)
Health Information Services
- ---------------------------
CareCentric Solutions, Series A, B
Inc. and C
Preferred 10/95-
shares 12/97 184,717 (168,204) (122,778)
CareCentric Solutions, Common share
Inc. warrant at
$.15;
expiring 12/02 12/97 15,525 (13,972) (13,972)
Medical/Diagnostic Equipment
- ----------------------------
Endocare, Inc. Common 08/96-
shares 01/97 152,400 0 434,264
Endocare, Inc. Common share
warrant at
$3.00;
expiring
08/01 08/96 30,000 0 55,125
R2 Technology, Series A-1
Inc. Preferred
shares 05/94 100,000 0 177,111
R2 Technology, Series B-1
Inc. Preferred
shares 03/96 17,134 0 33,229
Pharmaceuticals
- ---------------
Valentis, Inc.
(formerly Megabios Common 09/94-
Corp.) shares 07/95 100,424 0 (123,020)
--------- ---------
Total significant changes (182,176) 224,206
Other changes, net 0 (31,321)
--------- ---------
Total equity investments at June 30, 1999 $4,026,183 5,864,535
========= =========
</TABLE>
Marketable Equity Securities
- ----------------------------
Marketable equity securities had aggregate costs of $1,231,768 and $984,268
at June 30, 1999, and December 31, 1998, respectively, and aggregate fair
values of $1,560,631 and $868,154 at June 30, 1999 and December 31, 1998,
respectively. The net unrealized gain and loss at June 30, 1999, and
December 31, 1998, included gross gains of $326,360 and $118,852,
respectively.
CareCentric Solutions, Inc.
- ---------------------------
In July 1999, the company agreed to be acquired by Simione Central
Holdings, Inc. Based on the sales terms, the Partnership recorded a
$182,176 write-down of its investment in Preferred shares and common stock
warrants as of June 30, 1999.
Naiad Technologies, Inc.
- ------------------------
In June 1999, the Partnership recorded a $215,753 decrease in the fair
value of its investment based upon the Managing General Partners'
assessment of the operating status of the company.
R2 Technology, Inc.
- -------------------
In May 1999, the company completed a new round of financing in which the
Partnership did not participate. The pricing of this round indicated a
$214,002 increase in the fair value of the Partnership's preferred shares
and warrants.
Valentis, Inc. (formerly Megabios Corp.)
- ---------------------------------------
In May 1999, the Megabios Corp changed its name to Valentis, Inc.
Other Equity Investments
- ------------------------
Other significant changes reflected above relate to market value
fluctuations or the elimination of a discount relating to selling
restrictions for publicly traded portfolio companies.
5. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at June 30, 1999, and December 31, 1998,
consisted of:
<TABLE>
<CAPTION>
1999 1998
------ ------
<S> <C> <C>
Demand accounts $3,304 263
Money-market accounts 72 124
----- -------
Total $3,376 387
===== =======
</TABLE>
6. Short-Term Borrowings
---------------------
The Partnership has borrowing accounts with two financial institutions. At
June 30, 1999, the borrowing capacity of these accounts, which fluctuates
based on collateral value, was $457,200 and the outstanding balances
totaled $182,247; as of August 12, 1999, the outstanding balance was
$294,439. The weighted-average interest rate for the six months ended June
30, 1999 was 8.25%. Interest expense was $9,811 for the six months ended
June 30, 1999. The Partnership's investments in Endocare, Inc., Valentis,
Inc. (formerly Megabios Corp.) and Axys Pharmaceuticals, Inc. are pledged
as collateral.
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Liquidity and Capital Resources
- -------------------------------
During the six months ended June 30, 1999, net cash provided by operating
activities totaled $23,178. The Partnership paid management fees of
$36,649 to the Managing General Partners and received advances from the
Managing General Partners totaling $168,101 to fund its operations. In
addition, $18,549 was paid to the Individual General Partners as
compensation for their services. The Partnership paid other operating
expenses of $97,703. Dividend income of $7,978 was received.
The Partnership has borrowing accounts with two financial institutions.
The borrowing capacity of these accounts, which fluctuates based on
collateral value, was $457,200 and the outstanding balance was $182,247 at
June 30, 1999. As of August 12, 1999, the outstanding balance was
$294,439. The Partnership's investments in Endocare, Inc., Valentis, Inc.
(formerly Megabios Corp.) and Axys Pharmaceuticals, Inc. are pledged as
collateral. The Partnership, if required to by the lender, intends to
repay this borrowing from the proceeds of investment sales or support from
the Managing General Partners.
Cash and cash equivalents at June 30, 1999, were $3,376. Future proceeds
from investment sales along with Managing General Partners' support are
expected to be adequate to fund Partnership operations through the next
twelve months.
Results of Operations
- ---------------------
Current quarter compared to corresponding quarter in the preceding year
-----------------------------------------------------------------------
Net loss was $217,586 for the quarter ended June 30, 1999, compared to a
net income of $37,662 for the same period in 1998. The change was
primarily due to a $182,176 increase in realized losses from investment
write-downs and a $109,613 increase in operating expenses, partially offset
by a $32,410 increase in net unrealized fair value of equity investments.
Realized losses from investment write-downs totaled $182,176 in the quarter
ended June 30, 1999 and related to a portfolio company in the health
information services industry. There were no write-downs in the
corresponding quarter of 1998.
Total operating expenses were $125,960 for the quarter ended June 30, 1999,
compared to $16,347 for the same period in 1998. As explained in Note 3 to
the financial statements, the Managing General Partners absorbed $0 and
$62,535 for the quarters ended June 30, 1999 and 1998, respectively. The
decrease in operating expenses absorbed by the General Partners is
attributable to the re-evaluation of expense limitation provisions of the
Partnership agreement which occurred in the fourth quarter of 1998. This
re-evaluation effectively lowered the total amount of operating expenses
subject to the expense limitation. Had the limitation not been in effect,
operating expenses would have been $125,960 and $78,882 during the quarters
ended June 30, 1999 and 1998, respectively. The increase is primarily
attributable to increased investment monitoring and administrative overhead
costs, professional fees and interest on short-term borrowings.
The Partnership recorded an increase in equity investment fair value of
$135,167 for the quarter ended June 30, 1999 compared to an increase of
$102,757 for the same period in 1998. The 1999 increase was primarily due
to an increase in the medical/diagnostic equipment industries, partially
offset by a decrease in the environmental industry. The 1998 increase was
primarily due to increases in the biotechnology and medical/diagnostic
equipment industries.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
Current six months compared to corresponding six months in the
--------------------------------------------------------------
preceding year
--------------
Net loss was $111,050 for the six months ended June 30, 1999, compared to
net loss of $355,751 during the same period in 1998. The improvement was
primarily due to a $526,413 increase in the net unrealized fair value of
equity investments, which was partially offset by a $182,176 increase in
realized losses from investment write-downs and a $100,090 increase in
total operating expenses.
During the six months ended June 30, 1999 and 1998, the Partnership
recorded an increase in fair value of equity investments of $375,061 and a
decrease of $151,352, respectively. The 1999 increase was primarily due to
increases in the medical/diagnostic industry, partially offset by decreases
in the environmental and pharmaceutical industries. The 1998 decrease was
primarily due to decreases in the pharmaceutical industry, partially offset
by increases in the biotechnology industry.
Realized losses from investment write-downs totaled $182,176 for the six
months ended June 30, 1999 and related to a portfolio company in the health
information services industry. There were no write-downs in the
corresponding period of 1998.
Total operating expenses were $214,066 and $113,976 for the six months
ended June 30, 1999 and 1998, respectively. As discussed in Note 3 to the
financial statements, the Managing General Partners absorbed expenses of $0
and $62,535 for the six months ended June 30, 1999 and 1998, respectively.
The decrease in operating expenses absorbed by the General Partners is
attributable to the re-evaluation of expense limitation provisions of the
Partnership agreement which occurred in the fourth quarter of 1998. This
re-evaluation effectively lowered the total amount of operating expenses
subject to the expense limitation. Had the limitation not been in effect,
total operating expenses for the six months ended June 30, 1999 and 1998
would have been $214,066 and $176,511, respectively. The increase is
primarily attributable to increased administrative costs, professional fees
and interest on short-term borrowings.
YEAR 2000
- ---------
Widespread use of computer programs that use two digits rather than four to
store, calculate, and display year values in dates may cause computer
systems to malfunction in the year 2000, resulting in significant business
delays and disruptions.
The Partnership's State of Readiness
------------------------------------
Computer services are provided to the Partnership by its Managing General
Partner, Technology Funding Inc. ("TFI".) For several years, TFI has sought
to use Year 2000 compliant storage formats and algorithms in its
internally-developed and maintained systems. TFI has also completed
initial evaluations of computer systems, software, and embedded
technologies. Those evaluations confirmed that certain components of its
network server hardware and operating systems, voice mail system, e-mail
system, and accounting software may have Year 2000 compliance issues.
These resources and several less-critical components of the systems
environment were all scheduled as part of normal maintenance and
replacement cycles to be replaced or upgraded as Year 2000 compatible
components became available from vendors during 1998 and 1999. That
program remains on schedule to provide Year 2000 capable systems timely
without significant expenditures or disruption of Partnership operations.
However, the risk remains that TFI may not be able to verify whether Year
2000 compatibility claims by vendors are accurate, or whether changes
undertaken to achieve Year 2000 compatibility will create other undetected
problems in associated systems. Therefore, TFI anticipates that Year 2000
compliance testing and maintenance of these systems will continue as needed
into the first quarter of 2000.
As part of Year 2000 evaluation, TFI has also assembled a database listing
its significant suppliers to assess the extent to which it needs to prepare
for any of those parties' potential failure to remediate their Year 2000
compliance issues. TFI reviewed public Year 2000 statements of those
suppliers and sent questionnaires to mission-critical vendors whose public
statements were not adequate for assessment. All mission-critical vendors
have responded that they expect to be Year 2000 compliant barring any
unforeseen circumstances. TFI will continue to monitor its significant
suppliers as part of its Year 2000 evaluation. However, there can be no
guarantee that the systems of other companies on which TFI relies will be
timely converted, or that failure to convert will not have a material
adverse effect on the Partnership and its operations. TFI is also working
with the Partnership's portfolio companies to determine the extent to which
their operations are vulnerable to Year 2000 issues. There can be no
guarantee that the systems of portfolio companies in which the Partnership
has invested will be timely converted, or that their failure to convert
will not have a material adverse effect on the Partnership.
The Cost to Address Year 2000 Issues
------------------------------------
Expenditures in 1999 to date related to Year 2000 issues were not material
to the Partnership's financial statements. TFI expects that additional
expenditures for Year 2000 compliance will not be material to the
Partnership.
The Risks Associated with Year 2000 Issues
------------------------------------------
Any failure by the portfolio companies in which the Partnership has
invested, or by those portfolio companies' key suppliers or customers, to
anticipate and avoid Year 2000 related problems at reasonable cost could
have a material adverse effect on the value of and/or the timing of
realization of value from the Partnership's investments. If Year 2000
compliance issues are not resolved by December 31, 1999, internal system
failures or miscalculations could cause a temporary inability to process
transactions, loss of ability to send or receive e-mail and voice mail
messages, or disruptions in other normal business activities.
Additionally, failure of third parties on whom TFI relies to remediate
their Year 2000 issues timely could result in disruptions in the
Partnership's relationship with its financial institutions, temporary
disruptions in processing transactions, unanticipated costs, and problems
related to the Partnership's daily operations. While TFI continues to
address its internal Year 2000 issues, until TFI receives and evaluates
responses from a significant number of its suppliers, the overall risks
associated with the Year 2000 issue remain difficult to describe and
quantify. There can be no guarantee that the Year 2000 issue will not have
a material adverse effect on the Partnership and its operations.
TFI's Contingency Plan
----------------------
As part of its normal efforts to assure business continuation in the event
of natural disasters, systems failures, or other disruptions, TFI has
prepared contingency plans including an extensive Year 2000 contingency
plan. Taken together with TFI's Year 2000 remediation plan, it identifies
potential points of failure, approaches to correcting known Year 2000
problems, dates by which the preferred corrections are anticipated to be
made and tested, and alternative approaches if the corrections are not
completed timely or are later found to be inadequate. Although backup
systems and contingency approaches have been identified for most mission-
critical systems and vendor dependencies, there remain some systems for
which no good alternative exists, and there may be some problems that prove
more intractable than currently anticipated.
II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) No reports on Form 8-K were filed by the Partnership during the
quarter ended June 30, 1999.
(b) Financial Data Schedule for the six months ended and as of June 30,
1999 (Exhibit 27).
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING MEDICAL PARTNERS I, L.P.
By: TECHNOLOGY FUNDING INC.
Managing General Partner
Date: August 13, 1999 By: /s/Michael R. Brenner
-----------------------------------
Michael R. Brenner
Controller
<TABLE> <S> <C>
<ARTICLE>6
<LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE FORM 10-Q AS OF JUNE 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
<MULTIPLIER>1
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> JUN-30-1999
<PERIOD-TYPE> 6-MOS
<INVESTMENTS-AT-COST> 4,026,183
<INVESTMENTS-AT-VALUE> 5,864,535
<RECEIVABLES> 0
<ASSETS-OTHER> 6,593
<OTHER-ITEMS-ASSETS> 3,376
<TOTAL-ASSETS> 5,874,504
<PAYABLE-FOR-SECURITIES> 0
<SENIOR-LONG-TERM-DEBT> 0
<OTHER-ITEMS-LIABILITIES> 638,089
<TOTAL-LIABILITIES> 638,089
<SENIOR-EQUITY> 0
<PAID-IN-CAPITAL-COMMON> 3,398,063
<SHARES-COMMON-STOCK> 79,716
<SHARES-COMMON-PRIOR> 79,716
<ACCUMULATED-NII-CURRENT> 0
<OVERDISTRIBUTION-NII> 0
<ACCUMULATED-NET-GAINS> 0
<OVERDISTRIBUTION-GAINS> 0
<ACCUM-APPREC-OR-DEPREC> 1,838,352
<NET-ASSETS> 5,236,415
<DIVIDEND-INCOME> 7,978
<INTEREST-INCOME> 0
<OTHER-INCOME> 0
<EXPENSES-NET> 311,913
<NET-INVESTMENT-INCOME> (303,935)
<REALIZED-GAINS-CURRENT> (182,176)
<APPREC-INCREASE-CURRENT> 375,061
<NET-CHANGE-FROM-OPS> (111,050)
<EQUALIZATION> 0
<DISTRIBUTIONS-OF-INCOME> 0
<DISTRIBUTIONS-OF-GAINS> 0
<DISTRIBUTIONS-OTHER> 0
<NUMBER-OF-SHARES-SOLD> 0
<NUMBER-OF-SHARES-REDEEMED> 0
<SHARES-REINVESTED> 0
<NET-CHANGE-IN-ASSETS> (111,050)
<ACCUMULATED-NII-PRIOR> 0
<ACCUMULATED-GAINS-PRIOR> 0
<OVERDISTRIB-NII-PRIOR> 0
<OVERDIST-NET-GAINS-PRIOR> 0
<GROSS-ADVISORY-FEES> 79,298
<INTEREST-EXPENSE> 0
<GROSS-EXPENSE> 312,164
<AVERAGE-NET-ASSETS> 5,291,940
<PER-SHARE-NAV-BEGIN> 49
<PER-SHARE-NII> (6)
<PER-SHARE-GAIN-APPREC> 0 <F1>
<PER-SHARE-DIVIDEND> 0
<PER-SHARE-DISTRIBUTIONS> 0
<RETURNS-OF-CAPITAL> 0
<PER-SHARE-NAV-END> 43
<EXPENSE-RATIO> 5.9
<FN>
A zero value is used since the change in net unrealized fair value is
not allocated to General Partners and Limited Partners as it is not
taxable.
</FN>
</TABLE>
